Cisen Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	1,161	983.39	997.95	938.98
Short-Term Investments	-	357.58	154.11	236.27	-
Trading Asset Securities	-	1,275	1,638	1,550	1,485
Cash & Short-Term Investments	3,345	2,794	2,775	2,784	2,424
Cash Growth	19.74%	0.66%	-0.32%	14.87%	-4.46%
Accounts Receivable	-	1,257	1,363	1,272	1,048
Other Receivables	-	3.99	4.24	9.25	11.35
Receivables	-	1,261	1,367	1,281	1,060
Inventory	-	810.43	708.22	580.43	594.65
Other Current Assets	-	97.1	119.41	99.63	66.45
Total Current Assets	-	4,962	4,970	4,745	4,145
Property, Plant & Equipment	-	1,546	1,390	1,489	1,591
Long-Term Investments	-	665.48	602.27	265.08	308.01
Other Intangible Assets	-	203.97	211.6	213.03	210.82
Long-Term Deferred Tax Assets	-	77.41	79.83	86.72	81.65
Long-Term Deferred Charges	-	0.47	1.91	3.86	2.05
Other Long-Term Assets	-	98.74	81.94	12.87	25.54
Total Assets	-	7,554	7,338	6,815	6,364
Accounts Payable	-	549.49	468.01	459.71	434.97
Accrued Expenses	-	114.89	139.77	259.48	214.52
Short-Term Debt	-	71.98	34.8	57.79	130
Current Portion of Long-Term Debt	-	32.63	-	-	-
Current Portion of Leases	-	2.64	3.34	0.3	2.72
Current Income Taxes Payable	-	11.71	34.67	5.61	1.18
Current Unearned Revenue	-	78.11	100.16	118.78	70.05
Other Current Liabilities	-	627.39	589.17	380.24	365.5
Total Current Liabilities	-	1,489	1,370	1,282	1,219
Long-Term Debt	-	7.7	128.5	100	-
Long-Term Leases	-	0.89	4.03	0.51	10.91
Long-Term Unearned Revenue	-	57.17	56.25	65.36	74.43
Long-Term Deferred Tax Liabilities	-	12.28	12.68	11.46	3.87
Total Liabilities	-	1,567	1,571	1,459	1,308
Common Stock	-	452.75	452.78	453.31	453.33
Additional Paid-In Capital	-	1,929	1,919	1,913	1,863
Retained Earnings	-	3,570	3,358	2,989	2,774
Treasury Stock	-	-	-0.08	-19.77	-32.74
Comprehensive Income & Other	-	-2.71	-2.69	-2.93	-3.07
Total Common Equity	6,153	5,950	5,727	5,332	5,055
Minority Interest	-	37.39	39.1	23.64	0.75
Shareholders' Equity	6,194	5,987	5,766	5,356	5,056
Total Liabilities & Equity	-	7,554	7,338	6,815	6,364
Total Debt	43.06	115.83	170.67	158.61	143.63
Net Cash (Debt)	3,302	2,678	2,604	2,625	2,280
Net Cash Growth	23.31%	2.81%	-0.79%	15.15%	3.32%
Net Cash Per Share	7.29	5.89	5.75	5.78	5.05
Filing Date Shares Outstanding	447.5	452.75	452.76	451.36	449.83
Total Common Shares Outstanding	447.5	452.75	452.76	451.34	449.83
Working Capital	-	3,473	3,600	3,463	2,926
Book Value Per Share	13.59	13.14	12.65	11.81	11.24
Tangible Book Value	5,955	5,746	5,516	5,119	4,844
Tangible Book Value Per Share	13.15	12.69	12.18	11.34	10.77
Buildings	-	1,277	1,275	1,188	1,191
Machinery	-	2,109	2,092	1,903	1,797
Construction In Progress	-	405.8	66.68	207.17	199.71

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.